Profile data is unavailable for this security.
About the company
AdAlta Limited is an Australia-based clinical-stage biotechnology company. The Company uses its i-body platform to discover and develop protein therapeutics addressing drug targets that are challenging for other technologies. The Company's first-in-class lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. It is also engaged in developing i-body enabled Chimeric antigen receptor T cell (CAR-T) cells. It co-develops i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs.
- Revenue in AUD (TTM)1.78m
- Net income in AUD-5.38m
- Incorporated2006
- Employees--
- LocationAdalta LtdUnit 15 / 2 Park Drive, BundooraMELBOURNE 3083AustraliaAUS
- Phone+61 39479-5159
- Fax+61 39479-3666
- Websitehttps://adalta.com.au/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avecho Biotechnology Ltd | 339.30k | -3.48m | 6.34m | 29.00 | -- | 1.50 | -- | 18.68 | -0.0012 | -0.0012 | 0.0001 | 0.0013 | 0.0693 | 4.26 | 0.7043 | -- | -71.20 | -47.08 | -105.46 | -55.25 | -45.60 | 78.67 | -1,026.91 | -156.43 | 3.48 | -- | 0.0316 | -- | -58.07 | -19.42 | -46.71 | -- | -- | -- |
| Zelira Therapeutics Ltd | 1.02m | -36.57m | 8.51m | 8.00 | -- | -- | -- | 8.31 | -3.22 | -3.22 | 0.0902 | -0.3979 | 0.0524 | 0.0609 | 5.06 | -- | -188.05 | -46.98 | -246.20 | -50.16 | 91.73 | -- | -3,587.90 | -1,063.82 | 0.424 | -6.78 | 3.35 | -- | -82.72 | -35.59 | -556.18 | -- | -- | -- |
| Island Pharmaceuticals Ltd | 4.72k | -2.86m | 9.90m | -- | -- | 6.51 | -- | 2,096.89 | -0.0318 | -0.0318 | 0.00005 | 0.012 | 0.002 | -- | 0.0104 | -- | -124.17 | -- | -173.37 | -- | -- | -- | -60,684.75 | -- | -- | -544.58 | 0.2174 | -- | -57.45 | -- | -1.20 | -- | -- | -- |
| Adalta Ltd | 1.78m | -5.38m | 11.52m | -- | -- | 5.57 | -- | 6.45 | -0.0111 | -0.0111 | 0.0036 | 0.0034 | 0.2682 | -- | 0.7681 | -- | -80.88 | -66.85 | -203.94 | -114.23 | -- | -- | -301.55 | -175.59 | -- | -51.02 | 0.5712 | -- | -49.47 | -13.04 | -10.93 | -- | -18.22 | -- |
| Algorae Pharmaceuticals Ltd | 125.20k | -2.10m | 11.81m | -- | -- | 3.92 | -- | 94.34 | -0.0013 | -0.0013 | 0.00008 | 0.0018 | 0.0338 | -- | 1.81 | -- | -56.60 | -47.73 | -61.85 | -54.26 | -- | -- | -1,673.77 | -865.45 | -- | -115.69 | 0.00 | -- | 197.95 | -30.46 | 0.5741 | -- | -- | -- |
| Chimeric Therapeutics Ltd | 0.00 | -12.53m | 12.51m | -- | -- | 4.97 | -- | -- | -0.0136 | -0.0136 | 0.00 | 0.0028 | 0.00 | -- | -- | -- | -66.56 | -- | -194.88 | -- | -- | -- | -- | -- | -- | -58.48 | 0.5228 | -- | -- | -- | 50.86 | -- | -- | -- |
| Patrys Ltd | 1.39m | -3.54m | 14.40m | 15.00 | -- | 4.15 | -- | 10.33 | -0.0017 | -0.0017 | 0.0007 | 0.0017 | 0.2386 | -- | 0.6665 | -- | -60.57 | -52.81 | -68.65 | -56.79 | -- | -- | -253.86 | -249.64 | -- | -- | 0.00 | -- | -51.11 | 10.55 | 49.88 | -- | -4.41 | -- |
| BPH Energy Ltd | 843.69k | 4.56m | 14.47m | 2.00k | 3.12 | 0.4674 | -- | 17.15 | 0.0039 | 0.0039 | 0.0008 | 0.0257 | 0.0333 | -- | 11.41 | -- | 17.98 | 5.12 | 18.58 | 5.50 | -- | -- | 539.93 | 238.65 | -- | -- | 0.0029 | -- | 177.48 | 24.84 | 433.96 | -- | -- | -- |
| Medlab Clinical Ltd | 366.64k | -3.94m | 14.93m | 14.00 | -- | -- | -- | 40.71 | -1.73 | -1.73 | 0.1606 | -0.3068 | 0.1069 | -- | 5.82 | -- | -103.72 | -55.07 | -240.52 | -69.75 | 84.77 | 52.86 | -970.74 | -335.43 | -- | -342.19 | -- | -- | -28.90 | -29.83 | 18.55 | -- | -30.00 | -- |
| Rhythm Biosciences Ltd | 52.28k | -6.86m | 15.16m | -- | -- | 17.49 | -- | 290.06 | -0.0301 | -0.0301 | 0.0002 | 0.0035 | 0.0114 | 1.91 | 1.02 | -- | -148.83 | -134.13 | -199.13 | -168.97 | -4,946.29 | -1,807.84 | -13,115.47 | -9,433.23 | 1.58 | -1,750.40 | 0.1589 | -- | -77.10 | -18.01 | 16.56 | -- | -5.69 | -- |
| Alterity Therapeutics Ltd | 268.42k | -19.12m | 15.96m | 11.00 | -- | 1.14 | -- | 59.46 | -0.0052 | -0.0052 | 0.00007 | 0.0026 | 0.0115 | -- | 0.1307 | -- | -82.18 | -56.58 | -103.97 | -66.91 | -- | -- | -7,124.45 | -22,925.08 | -- | -- | 0.0114 | -- | 1,532.73 | 19.85 | -38.51 | -- | -4.01 | -- |
| BTC Health Ltd | 16.36k | 1.06m | 16.21m | 1.00 | 14.49 | 3.28 | 15.36 | 990.60 | 0.0035 | 0.0035 | 0.00005 | 0.0153 | 0.004 | -- | -- | -- | 26.09 | -21.22 | 27.32 | -22.60 | -- | -- | 6,450.37 | -3,306.65 | -- | -- | 0.00 | -- | 23.38 | -38.62 | 110.38 | -- | -- | -- |
Data as of Sep 23 2024. Currency figures normalised to Adalta Ltd's reporting currency: Australian Dollar AUD
